prescribing information - Purdue Pharma (Canada)
... dose of the opioid analgesic, and titrate based on clinical response. Follow patients closely for signs and symptoms of respiratory depression and sedation. Advise both patients and caregivers about the risks of respiratory depression and sedation when Dilaudid is used with benzodiazepines or other ...
... dose of the opioid analgesic, and titrate based on clinical response. Follow patients closely for signs and symptoms of respiratory depression and sedation. Advise both patients and caregivers about the risks of respiratory depression and sedation when Dilaudid is used with benzodiazepines or other ...
Clinical Concepts - Addiction Treatment Forum
... of patients reporting side effects was similar among groups. At least one side effect was reported by 55% of those administered LAAM, 49% receiving buprenorphine, and 45% of high-dose methadone patients. The most common adverse reactions were constipation in 21% of reports, followed by nausea (8%), ...
... of patients reporting side effects was similar among groups. At least one side effect was reported by 55% of those administered LAAM, 49% receiving buprenorphine, and 45% of high-dose methadone patients. The most common adverse reactions were constipation in 21% of reports, followed by nausea (8%), ...
BuTrans 5 10 20
... BuTrans is contraindicated in opioid dependent patients, for narcotic withdrawal treatment or in pregnant women (see CONTRAINDICATIONS). In France, neonatal withdrawal has been reported in infants of women treated with sublingual buprenorphine for drug-addiction during pregnancy. Time to onset of wi ...
... BuTrans is contraindicated in opioid dependent patients, for narcotic withdrawal treatment or in pregnant women (see CONTRAINDICATIONS). In France, neonatal withdrawal has been reported in infants of women treated with sublingual buprenorphine for drug-addiction during pregnancy. Time to onset of wi ...
Fentanyl Buccal Lozenges (Actiq®)
... FDA-approved, oral fentanyl citrate has been studied in non-opioid tolerant patients as young as 2 years of age for various indications including surgical procedure pain, wound dressing changes in burn patients, and sedation in single doses ranging from 10-20 μg/kg given prior to procedures with mix ...
... FDA-approved, oral fentanyl citrate has been studied in non-opioid tolerant patients as young as 2 years of age for various indications including surgical procedure pain, wound dressing changes in burn patients, and sedation in single doses ranging from 10-20 μg/kg given prior to procedures with mix ...
PROLOPA Product Monograph
... disease with the exception of drug-induced parkinsonism. The administration of PROLOPA is associated with amelioration of the symptoms of Parkinson’s disease with the advantage that combined therapy significantly diminishes the incidence of the levodopa-induced peripheral side-effects of nausea, vom ...
... disease with the exception of drug-induced parkinsonism. The administration of PROLOPA is associated with amelioration of the symptoms of Parkinson’s disease with the advantage that combined therapy significantly diminishes the incidence of the levodopa-induced peripheral side-effects of nausea, vom ...
PRODUCT MONOGRAPH GARASONE OPHTHALMIC AND OTIC
... To avoid possible contamination and cross-infection, avoid the use of the same bottle of medication for the treatment of otic and ocular infections. The use of this dispenser by more than one person may spread infection. Contamination may occur if the dropper tip touches any surface. Do not allow di ...
... To avoid possible contamination and cross-infection, avoid the use of the same bottle of medication for the treatment of otic and ocular infections. The use of this dispenser by more than one person may spread infection. Contamination may occur if the dropper tip touches any surface. Do not allow di ...
Department for Transport - Over-the
... review the information provided to the consumer about their sedative properties. It is very difficult to monitor the amount of OTC medication being taken by the general public. Some medications are available for night-time use only, due to their sedative effects, including those specifically for the ...
... review the information provided to the consumer about their sedative properties. It is very difficult to monitor the amount of OTC medication being taken by the general public. Some medications are available for night-time use only, due to their sedative effects, including those specifically for the ...
Lithium Carbonate Extended-Release Tablets 300mg
... did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly pati ...
... did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly pati ...
Page 1 of 9 Clinical Policy: aflibercept (Eylea), ranibizumab
... Appendix B: General Information This section is reserved for information that would be useful in making a coverage determination, such as definitions of therapeutic failure not listed in the usage guideline section. ...
... Appendix B: General Information This section is reserved for information that would be useful in making a coverage determination, such as definitions of therapeutic failure not listed in the usage guideline section. ...
Dear Dr Neurologist - Fluoroquinolone Toxicity of the Thyroid
... labels and Medication Guides for all fluoroquinolone antibacterial drugs be updated to better describe the serious side effect of peripheral neuropathy. This serious nerve damage potentially caused by fluoroquinolones (see Table for a list) may occur soon after these drugs are taken and may be perma ...
... labels and Medication Guides for all fluoroquinolone antibacterial drugs be updated to better describe the serious side effect of peripheral neuropathy. This serious nerve damage potentially caused by fluoroquinolones (see Table for a list) may occur soon after these drugs are taken and may be perma ...
Key Test Findings Affiliated Genetics
... Consider prescribing a lower flecainide dose. When compared to a CYP2D6 normal metabolizer, a poor metabolizer may require a 50% dose reduction.Careful titration with ECG recording and monitoring of flecainide plasma concentrations are recommended until a favorable clinical response is achieved. Flu ...
... Consider prescribing a lower flecainide dose. When compared to a CYP2D6 normal metabolizer, a poor metabolizer may require a 50% dose reduction.Careful titration with ECG recording and monitoring of flecainide plasma concentrations are recommended until a favorable clinical response is achieved. Flu ...
The Long-Term Management of Uveitis
... many studies in uveitis tend to focus on only one active treatment arm. Moreover, multiple different therapies were used in the systemic arm, which, again, reflects how varied the approach is to uveitis in clinical practice. Another point about MUST is that we have long-term follow up out to 54 mont ...
... many studies in uveitis tend to focus on only one active treatment arm. Moreover, multiple different therapies were used in the systemic arm, which, again, reflects how varied the approach is to uveitis in clinical practice. Another point about MUST is that we have long-term follow up out to 54 mont ...
Ziprasidon Pfizer capsule hard ENG SmPC
... controlled clinical trials, the combination of ziprasidone plus lithium has not demonstrated an increased clinical risk, compared to lithium alone. There are limited data on co-medication with the mood stabiliser carbamazepine. A pharmacokinetic interaction of ziprasidone with valproate is unlikely ...
... controlled clinical trials, the combination of ziprasidone plus lithium has not demonstrated an increased clinical risk, compared to lithium alone. There are limited data on co-medication with the mood stabiliser carbamazepine. A pharmacokinetic interaction of ziprasidone with valproate is unlikely ...
Deadly pediatric poisons: nine common agents that kill at low doses
... 9264 CCA exposures in 2001, a 100% increase from 1990 [2,13]. Of the 9264 exposures reported in 2001, 2249 occurred in children younger than 6 years old. Pediatric-specific data from 1998 revealed 2197 exposures in children age 5 years or younger, with 88 moderate to major outcomes. No pediatric deat ...
... 9264 CCA exposures in 2001, a 100% increase from 1990 [2,13]. Of the 9264 exposures reported in 2001, 2249 occurred in children younger than 6 years old. Pediatric-specific data from 1998 revealed 2197 exposures in children age 5 years or younger, with 88 moderate to major outcomes. No pediatric deat ...
SOTALOL HYDROCHLORIDE TABLETS, USP 80 mg, 120 mg, 160
... of sustained VT/VF who were also inducible by PES, the effectiveness acutely and chronically of sotalol hydrochloride was compared with 6 other drugs (procainamide, quinidine, mexiletine, propafenone, imipramine and pirmenol). Overall response, limited to first randomized drug, was 39% for sotalol a ...
... of sustained VT/VF who were also inducible by PES, the effectiveness acutely and chronically of sotalol hydrochloride was compared with 6 other drugs (procainamide, quinidine, mexiletine, propafenone, imipramine and pirmenol). Overall response, limited to first randomized drug, was 39% for sotalol a ...
details - Global Pharmaceuticals Pakistan
... Pediatric use Clinical studies have been conducted evaluating delayed-release omeprazole in pediatric patients. There are no adequate and well-controlled studies in pediatric patients with Rapid (Omeprazole/sodium Bicarbonate) Geriatric use: Pharmacokinetic studies with buffered omeprazole have show ...
... Pediatric use Clinical studies have been conducted evaluating delayed-release omeprazole in pediatric patients. There are no adequate and well-controlled studies in pediatric patients with Rapid (Omeprazole/sodium Bicarbonate) Geriatric use: Pharmacokinetic studies with buffered omeprazole have show ...
Traumeel Zeel Injection Booklet
... Injection Solution Injection Solution: Allergic (hypersensitivity) reactions (e.g. skin allergies, redness/swelling at the injection site, even up to anaphylaxis) may occur in isolated cases. • Adverse event rates observed in the Monotherapy use of Zeel® Injection Solution:Allergic (hypersensitivity ...
... Injection Solution Injection Solution: Allergic (hypersensitivity) reactions (e.g. skin allergies, redness/swelling at the injection site, even up to anaphylaxis) may occur in isolated cases. • Adverse event rates observed in the Monotherapy use of Zeel® Injection Solution:Allergic (hypersensitivity ...
product information
... In the controlled studies, weight gain occurred more frequently in patients treated with LYRICA than in patients treated with placebo. LYRICA associated weight gain was related to dose and length of exposure, but did not appear to be associated with baseline BMI, gender or age. In accordance with cu ...
... In the controlled studies, weight gain occurred more frequently in patients treated with LYRICA than in patients treated with placebo. LYRICA associated weight gain was related to dose and length of exposure, but did not appear to be associated with baseline BMI, gender or age. In accordance with cu ...
sodium lactate
... limited use has been inadequate to fully define proper dosage and limitations for use. Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should ...
... limited use has been inadequate to fully define proper dosage and limitations for use. Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should ...
ANNEX I TO PSUR CORE SAFETY PROFILE (EU SPC Sections 4.2
... interactions will be less pronounced for the rectal than for the oral route because the gastro-intestinal tract is by-passed whereas after IM administration the effects of CYP3A4 modulation should not substantially differ from those seen with IV midazolam. It is therefore recommended to carefully mo ...
... interactions will be less pronounced for the rectal than for the oral route because the gastro-intestinal tract is by-passed whereas after IM administration the effects of CYP3A4 modulation should not substantially differ from those seen with IV midazolam. It is therefore recommended to carefully mo ...
Prescribing information
... LAMISIL Oral Granules, perform liver function tests because hepatotoxicity may occur in patients with and without preexisting liver disease. Cases of liver failure, some leading to liver transplant or death, have occurred with the use of oral terbinafine during postmarketing experience in individual ...
... LAMISIL Oral Granules, perform liver function tests because hepatotoxicity may occur in patients with and without preexisting liver disease. Cases of liver failure, some leading to liver transplant or death, have occurred with the use of oral terbinafine during postmarketing experience in individual ...
sodium lactate - Pfizer Injectables
... limited use has been inadequate to fully define proper dosage and limitations for use. Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should ...
... limited use has been inadequate to fully define proper dosage and limitations for use. Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should ...
Loxamine - Medsafe
... Haemorrhage: Bleeding abnormalities of the skin and mucous membranes have been reported with the use of SSRIs (including purpura, haematoma, epistaxis, gynaecological bleeding and gastrointestinal bleeding). This risk may be potentiated by concurrent use of non-steroidal antiinflammatory drugs (NSA ...
... Haemorrhage: Bleeding abnormalities of the skin and mucous membranes have been reported with the use of SSRIs (including purpura, haematoma, epistaxis, gynaecological bleeding and gastrointestinal bleeding). This risk may be potentiated by concurrent use of non-steroidal antiinflammatory drugs (NSA ...
PACLitaxel - Cancer Care Ontario
... The most frequent dose-limiting events are myelosuppression, neuropathy, hypersensitivity reactions and musculoskeletal effects. Myelosuppression is dose and schedule-dependent but is not cumulative, with neutropenia being less common when paclitaxel was given as a 3-hour infusion as compared to a 2 ...
... The most frequent dose-limiting events are myelosuppression, neuropathy, hypersensitivity reactions and musculoskeletal effects. Myelosuppression is dose and schedule-dependent but is not cumulative, with neutropenia being less common when paclitaxel was given as a 3-hour infusion as compared to a 2 ...
Optometry Times
... assessment of a new multi-purpose disinfecting solution in asymptomatic and symptomatic patients. Poster presented at: AAO; December 2006; Denver, CO. 3. Meadows D, Ketelson H, Napier L, Christensen M, Mathis J. Clinical ex vivo wettability of traditional and silicone hydrogel soft contact lenses. P ...
... assessment of a new multi-purpose disinfecting solution in asymptomatic and symptomatic patients. Poster presented at: AAO; December 2006; Denver, CO. 3. Meadows D, Ketelson H, Napier L, Christensen M, Mathis J. Clinical ex vivo wettability of traditional and silicone hydrogel soft contact lenses. P ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.